The reported exploration to sell Watson Health, the AI-driven health business of IBM, underscores deep challenges with technology in solving healthcare problems, according to the Wall Street Journal.
WSJ, which broke the anonymously sourced news that IBM might be looking to unload Watson Health, notes that massive datasets likely can’t solve healthcare’s biggest issues, as some tech and business solutions companies have touted. When it comes to complex medical needs, AI “can be difficult to apply,” the paper points out.
That’s because healthcare professionals may not have all the answers, with gaps in knowledge for some health conditions. AI is trained on data to help healthcare professionals make diagnoses and care decisions, and if the data is imperfect, as it often is with complex health conditions, the technology solutions are imperfect too.
Further, it is difficult––or even impossible––to compute patient preferences. For example, the behavior of a young adult who refuses a COVID-19 vaccine isn’t predictable, and therefore computable, according to the report. That issue just can’t be solved with AI.
However, there are a number of healthcare areas where AI can solve problems and improve efficiencies. Helping doctors diagnose patients is one area, as AI can pick up repetitive patterns in images to identify and classify MRI or X-rays. Health insurance giant Humana recently teamed up with IBM Watson Health to introduce a conversational AI solution for its employer group members, enabling an AI assistant to answer questions for customers.
Neural networks and wearable devices are also gaining traction as successful ways to implement AI in healthcare, collecting vast amounts of data that can be used to identify early health risks and potential interventions.
As AI continues to expand in healthcare, its uses will continue to develop. But solving healthcare’s biggest and most complex challenges, like curing cancer, may still be a long way off.
“I believe that we’re many years away from AI products that really positively impact clinical care for many patients,” Bob Kocher, MD, partner at Venrock and a former White House health adviser under President Barack Obama, tells the WSJ.